Qualigen Therapeutics, Inc. (QLGN) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Qualigen Therapeutics, Inc. is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's current portfolio consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical program (Pan-RAS). The company divested its former diagnostics subsidiary, Qualigen, Inc., and its majority interest in NanoSynex in July 2023; results from these entities are reported as discontinued operations.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Total Expenses | $1,268,581 | $2,778,363 | $4,428,676 | $9,030,895 |
| Net Loss (Continuing Ops) | $(1,794,060) | $(3,235,025) | $(5,303,368) | $(10,007,448) |
| Net Loss (Total) | $(1,794,060) | $(3,695,063) | $(5,403,368) | $(11,310,001) |
| Cash and Equivalents | $388,152 | $2,073,849 | $388,152 | $2,073,849 |
| Current Liabilities | $4,453,845 | $4,136,805 | $4,453,845 | $4,136,805 |
| Convertible Debt (Current) | $1,434,231 | $1,299,216 | $1,434,231 | $1,299,216 |
| Warrant Liabilities | $274,042 | $54,600 | $274,042 | $54,600 |
| Derivative Liabilities | $536,977 | $0 | $536,977 | $0 |
Note: The company reported no revenue from continuing operations. Discontinued operations contributed a loss of $100,000 for the nine months ended September 30, 2024.
Material Changes vs. Prior Period
- Expense Reduction: Total expenses decreased significantly year-over-year. For the nine months ended September 30, 2024, expenses dropped from $9.0 million to $4.4 million. This was driven by a 68% reduction in R&D expenses (from $3.9M to $1.2M) and a 38% reduction in G&A expenses (from $5.1M to $3.2M), primarily due to lower payroll, reduced stock-based compensation, and decreased program costs for QN-302 and Pan-RAS.
- Debt and Derivatives: The company issued new convertible debentures in 2024, resulting in the recognition of derivative liabilities totaling approximately $537,000 as of September 30, 2024, compared to zero in the prior year. This included a loss of $321,080 on the change in fair value of derivative liabilities for the nine-month period.
- Financing Activity: The company raised approximately $3.1 million in net proceeds from a public offering of common stock and prefunded warrants in September 2024. Additionally, $1.5 million was raised via convertible debt and $2.0 million via a senior note (which was repaid in September 2024).
- Accounts Payable Settlement: The company recognized a gain of $348,305 in Q3 2024 from settling outstanding accounts payable.
Guidance, Outlook, and Risks
- Liquidity and Going Concern: Management states that cash balances are expected to fund operations only through the fourth quarter of 2024. The filing explicitly raises substantial doubt about the company's ability to continue as a going concern for the one-year period following the issuance date. There is no assurance that profitable operations will ever be achieved.
- Delisting Risk: The company received an extension from Nasdaq until November 19, 2024, to regain compliance with the Bid Price Rule and Equity Rule. Failure to comply by this date may result in delisting.
- Reverse Stock Split: A 1-for-50 reverse stock split was approved by shareholders and became effective on November 5, 2024.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, specifically regarding insufficient accounting personnel and lack of effective IT general controls. These weaknesses were not remediated during the quarter.
- Strategic Partnerships: The company entered a Co-Development Agreement with Marizyme, Inc., providing up to $1.75 million in funding in exchange for potential royalty payments on Marizyme's DuraGraft product.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to secure additional financing before the end of Q4 2024 to avoid insolvency.
- Nasdaq Compliance: Monitor stock price performance to ensure compliance with Nasdaq listing standards by the November 19, 2024 deadline.
- Debt Conversion Terms: Review the terms of the 2024 Alpha and Chen Debentures, specifically the "ratchet" antidilution provisions that have already triggered significant conversion price reductions (to $6.50/share), which may lead to further dilution.
- Derivative Liability Volatility: Assess the impact of stock price fluctuations on the fair value of warrant and derivative liabilities, which can cause significant non-cash volatility in net loss.
- Internal Control Remediation: Evaluate the plan and funding required to remediate the material weaknesses in internal controls over financial reporting.